Abstract
This study aimed to evaluate if macular autofluorescence (MAF) is a valuable, non-invasive follow-up parameter for cystoid macular edema. A total of 71 eyes (71 cases) with cystoid macular edema (CME) were included in the study. Macular pigment (MP) was evaluated using HRA2 (infrared) IF and FA models. The density of MP was graded into three categories: without, partial, and normal amount of MP. A comparison was made between the baseline (before the first administration) level and at the fourth month, following three consecutive intravitreal lucentis injections every month. The morphology and distribution of MAF, and the density and distribution of MP were regarded as the main outcome measures. At the baseline visit, all eyes with CME had petaloid/irregular-shaped MAF in the macular area (100%). No MAF was detected in the control eyes (0). There was significant difference in MAF between the CME and normal groups (P=0.000). At the fourth monthly visit, normal levels of MP density without MAF was detected in 68 eyes (95.8%) with the best corrected spectacular visual acuity increasing to at least 1 line accordingly. We conclude that macular MAF can be used as a follow-up parameter for patients with CME. MP and MAF can indirectly reflect the fovea cone function.
Highlights
Cystoid macular edema (CME), which is characterized by cystic retinal thickening or lipid deposition, still remains one of the major causes of blindness
We evaluate the correlation of AF and macular pigment density in patients with pre- and post- lucentis treated CME, and further aim to provide a non-invasive routine follow-up tool by studying the correlations of the macular pigment density and the morphology of macular edema
We evaluated the correlation between macular autofluorescence (MAF) and the Macular pigment (MP) density pre- and post- lucentis intravitreal injection
Summary
A total of 71 eyes (71 cases) with DME (16 eyes), CME secondary to central vein occlusion (CRVO, 30 eyes) and branch vein occlusion (BRVO, 23 eyes) Coat’s disease (2 eyes), and non-infectious uveitis that received intravitreal injections of lucentis in Beijing Tongren Eye Center from 2012.8–2013.10 were included in this study. Enrolled in this study were 38 males and 33 females, aged 27–82 years old (54.82±14.70) with a minimum follow-up of one year. DME, CME secondary to BRVO, CRVO, non-infectious uveitis and Coat’s disease were diagnosed using the patient’s medical history, indirect ophthalmoscopy, mydriatic fundus photography and fluorescein fundus angiography (FFA). Changed BSVA was defined as a loss or gain of more than 10 logMAR letters; otherwise, it was defined as unchanged. Eyes were followed up by BSVA, AF, MP and OCT every month
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
